<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Exclude categories &#8211; BJC TV</title>
	<atom:link href="https://tv.bjcardio.co.uk/tag/exclude-categories/feed/" rel="self" type="application/rss+xml" />
	<link>https://tv.bjcardio.co.uk</link>
	<description>Short video updates for cardiologists</description>
	<lastBuildDate>Wed, 19 Aug 2026 14:16:09 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://tv.bjcardio.co.uk/wp-content/uploads/2023/06/cropped-favicon-32x32.png</url>
	<title>Exclude categories &#8211; BJC TV</title>
	<link>https://tv.bjcardio.co.uk</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>The barriers to early diagnosis of cardiac amyloidosis in women</title>
		<link>https://tv.bjcardio.co.uk/featured-videos-1/the-barriers-to-early-diagnosis-of-cardiac-amyloidosis-in-women/</link>
		
		<dc:creator><![CDATA[jleiwy@omniamed.com]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 08:18:37 +0000</pubDate>
				<category><![CDATA[Educational material from Pfizer]]></category>
		<category><![CDATA[Featured videos #1]]></category>
		<category><![CDATA[Exclude categories]]></category>
		<category><![CDATA[Exclude-carousel]]></category>
		<category><![CDATA[Exclude-videolistingpage]]></category>
		<category><![CDATA[Featured Videos #1]]></category>
		<category><![CDATA[Pfizer 2026]]></category>
		<category><![CDATA[SidebarExclude]]></category>
		<category><![CDATA[Sponsored]]></category>
		<guid isPermaLink="false">https://tv.bjcardio.co.uk/?p=11313</guid>

					<description><![CDATA[In this short video, Professor Fontana discusses the barriers women face in the diagnosis of cardiac amyloidosis.]]></description>
										<content:encoded><![CDATA[
<h5 class="wp-block-heading">Speaker</h5>



<p class="wp-block-paragraph"><strong>Professor Marianna Fontana</strong>, Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, University College London</p>



<p class="wp-block-paragraph">For more expert-led non-promotional content on heart failure, cardiac amyloidosis and ATTR-CM, please visit the <a href="https://www.pfizermedical.co.uk/therapy-areas/cardiovascular" rel="nofollow noopener" target="_blank">Pfizer Medical website</a>. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.</p>



<p class="wp-block-paragraph">Abbreviation:<br>ATTR-CM: Transthyretin amyloid cardiomyopathy.</p>



<p style="color: black; font-size: 14px; margin-top: 20px;">PP-UNP-GBR-14079 | March 2026</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>British Society of Echocardiography guideline for the TTE assessment of cardiac amyloidosis and the role of ECHO in monitoring disease progression in cardiac amyloidosis</title>
		<link>https://tv.bjcardio.co.uk/featured-videos-1/british-society-of-echocardiography-guideline-for-the-tte-assessment-of-cardiac-amyloidosis-and-the-role-of-echo-in-monitoring-disease-progression-in-cardiac-amyloidosis/</link>
		
		<dc:creator><![CDATA[jleiwy@omniamed.com]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 08:16:57 +0000</pubDate>
				<category><![CDATA[Educational material from Pfizer]]></category>
		<category><![CDATA[Featured videos #1]]></category>
		<category><![CDATA[Exclude categories]]></category>
		<category><![CDATA[Exclude-videolistingpage]]></category>
		<category><![CDATA[Featured Videos #1]]></category>
		<category><![CDATA[Pfizer 2026]]></category>
		<category><![CDATA[Pfizer amyloidosis series 2026]]></category>
		<category><![CDATA[SidebarExclude]]></category>
		<category><![CDATA[Sponsored]]></category>
		<guid isPermaLink="false">https://tv.bjcardio.co.uk/?p=11298</guid>

					<description><![CDATA[In this short video, Dr Moody discusses the British Society of Echocardiography guidelines for the TTE assessment of cardiac amyloidosis, and monitoring disease progression.]]></description>
										<content:encoded><![CDATA[
<h5 class="wp-block-heading">Speaker</h5>



<p class="wp-block-paragraph"><strong>Dr William E Moody,</strong> Consultant Cardiologist, Queen Elizabeth Hospital, Birmingham</p>



<p class="wp-block-paragraph">For more expert-led non-promotional content on heart failure, cardiac amyloidosis and transthyretin amyloid cardiomyopathy, please visit the <a href="https://www.pfizermedical.co.uk/therapy-areas/cardiovascular" rel="nofollow noopener" target="_blank">Pfizer Medical website</a>. Clicking this link will redirect you to the Pfizer Medical website, a non-promotional website developed and funded by Pfizer Ltd. for UK healthcare professionals.</p>



<h5 class="wp-block-heading">Reference</h5>



<p class="wp-block-paragraph">Moody, William E <em>et al</em>. “British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.” Echo research and practice vol. 10,1 13. 31 Aug. 2023, doi:10.1186/s44156-023-00028-7</p>



<p class="wp-block-paragraph">Abbreviations:<br>ECHO: echocardiography; TTE: transthoracic echocardiography.</p>



<p style="color: black; font-size: 14px; margin-top: 20px;">PP-UNP-GBR-14075 | March 2026</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Heart Failure Foundation Course: Managing renal function in people with heart failure with reduced ejection fraction</title>
		<link>https://tv.bjcardio.co.uk/renal-medicine/heart-failure-foundation-course-managing-renal-function-in-people-with-heart-failure-with-reduced-ejection-fraction/</link>
		
		<dc:creator><![CDATA[jleiwy@omniamed.com]]></dc:creator>
		<pubDate>Wed, 29 Oct 2025 15:27:50 +0000</pubDate>
				<category><![CDATA[Featured videos #1]]></category>
		<category><![CDATA[Heart failure]]></category>
		<category><![CDATA[Renal medicine]]></category>
		<category><![CDATA[Exclude categories]]></category>
		<category><![CDATA[Featured Videos #1]]></category>
		<category><![CDATA[Novartis Series]]></category>
		<category><![CDATA[Sponsored]]></category>
		<guid isPermaLink="false">https://tv.bjcardio.co.uk/?p=10344</guid>

					<description><![CDATA[Dr Will Petchey (Consultant Nephrologist, West Suffolk and Cambridge University Hospital Trusts) summarises the third session of the Heart Failure Foundation Course 2025, which explores the critical link between heart and kidney health in managing heart failure with reduced ejection fraction.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><a href="https://resources.gpnotebook.com/heart-failure-foundation-course-hffc-2025-on-demand/" rel="nofollow noopener" target="_blank">Watch the full on-demand video and the other videos in this series on the Heart Failure Foundation Course 2025 resource site</a>.</p>



<p style="text-align: center; border-width:1px; padding:5px;">Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard" target="_blank" rel="noreferrer noopener nofollow">www.mhra.gov.uk/yellowcard</a>. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at <a href="http://www.novartis.com/report" target="_blank" rel="noreferrer noopener nofollow">www.novartis.com/report</a> or alternatively email <a href="mailto:medinfo.uk@novartis.com" target="_blank" rel="noreferrer noopener">medinfo.uk@novartis.com</a> or call 01276 698370.</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Heart Failure Foundation Course: Optimising treatment for people with chronic heart failure with reduced ejection fraction</title>
		<link>https://tv.bjcardio.co.uk/featured-videos-1/heart-failure-foundation-course-optimising-treatment-for-people-with-chronic-heart-failure-with-reduced-ejection-fraction/</link>
		
		<dc:creator><![CDATA[jleiwy@omniamed.com]]></dc:creator>
		<pubDate>Wed, 29 Oct 2025 15:26:36 +0000</pubDate>
				<category><![CDATA[Featured videos #1]]></category>
		<category><![CDATA[Heart failure]]></category>
		<category><![CDATA[Exclude categories]]></category>
		<category><![CDATA[Featured Videos #1]]></category>
		<category><![CDATA[Novartis Series]]></category>
		<category><![CDATA[Sponsored]]></category>
		<guid isPermaLink="false">https://tv.bjcardio.co.uk/?p=10324</guid>

					<description><![CDATA[Professor Jawad Khan (Consultant Interventional Cardiologist and Director of Medical Education, Sandwell and West Birmingham NHS Trust) introduces the second session of the Heart Failure Foundation Course 2025, which explores available treatment options and the practicalities of rapid uptitration of guideline-directed medication for patients with chronic heart failure with reduced ejection fraction.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><a href="https://resources.gpnotebook.com/heart-failure-foundation-course-hffc-2025-on-demand/" rel="nofollow noopener" target="_blank">Watch the full on-demand video and the other videos in this series on the Heart Failure Foundation Course 2025 resource site</a>.</p>



<p style="text-align: center; border-width:1px; padding:5px;">Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard" target="_blank" rel="noreferrer noopener nofollow">www.mhra.gov.uk/yellowcard</a>. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at <a href="http://www.novartis.com/report" target="_blank" rel="noreferrer noopener nofollow">www.novartis.com/report</a> or alternatively email <a href="mailto:medinfo.uk@novartis.com" target="_blank" rel="noreferrer noopener">medinfo.uk@novartis.com</a> or call 01276 698370.</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Heart Failure Foundation Course: Chronic heart failure with reduced ejection fraction: Burden, symptoms and diagnosis</title>
		<link>https://tv.bjcardio.co.uk/featured-videos-1/heart-failure-foundation-course-chronic-heart-failure-with-reduced-ejection-fraction-burden-symptoms-and-diagnosis/</link>
		
		<dc:creator><![CDATA[jleiwy@omniamed.com]]></dc:creator>
		<pubDate>Wed, 29 Oct 2025 15:25:10 +0000</pubDate>
				<category><![CDATA[Featured videos #1]]></category>
		<category><![CDATA[Heart failure]]></category>
		<category><![CDATA[Exclude categories]]></category>
		<category><![CDATA[Featured Videos #1]]></category>
		<category><![CDATA[Novartis Series]]></category>
		<category><![CDATA[Sponsored]]></category>
		<guid isPermaLink="false">https://tv.bjcardio.co.uk/?p=10311</guid>

					<description><![CDATA[Maggie Simpson (Registered Nurse, NHS Scotland) introduces the first session of the Heart Failure Foundation Course 2025. This session explores the burden and symptoms of chronic heart failure with reduced ejection fraction, as well as the key steps involved in diagnosing the condition.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><a href="https://resources.gpnotebook.com/heart-failure-foundation-course-hffc-2025-on-demand/" rel="nofollow noopener" target="_blank">Watch the full on-demand video and the other videos in this series on the Heart Failure Foundation Course 2025 resource site</a>.</p>



<p style="text-align:center;border-width:1px;padding:5px;">Adverse events should be reported. Reporting forms and information can be found at <a href="http://www.mhra.gov.uk/yellowcard" rel="nofollow noopener" target="_blank">www.mhra.gov.uk/yellowcard</a>. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at <a href="http://www.novartis.com/report" rel="nofollow noopener" target="_blank">www.novartis.com/report</a> or alternatively email <a href="mailto:medinfo.uk@novartis.com" target="_blank" rel="noreferrer noopener">medinfo.uk@novartis.com</a> or call 01276 698370.</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
